Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued Sort ascending
Invega Sustenna Paliperidone palmitate Schizophrenia Do not list Complete
Uloric Febuxostat Gout List with clinical criteria and/or conditions Complete
Vimpat Lacosamide Epilepsy, partial onset seizures List with clinical criteria and/or conditions Complete
VPRIV Velaglucerase alfa Gaucher Disease List with clinical criteria and/or conditions Complete
Prolia Denosumab Osteoporosis, postmenopausal women List with clinical criteria and/or conditions Complete
Effient Prasugrel hydrochloride Acute Coronary Syndrome Do not list Complete
Finacea Azelaic acid Rosacea List Complete
Ilaris Canakinumab Cryopyrin-Associated Periodic Syndrome Do not list Complete
Kuvan Sapropterin dihydrochloride Phenylketonuria (PKU) Do not list Complete
Actemra Tocilizumab Arthritis, Rheumatoid List with clinical criteria and/or conditions Complete